Delcath Systems (NASDAQ:DCTH) Downgraded by StockNews.com to Sell

StockNews.com lowered shares of Delcath Systems (NASDAQ:DCTH) from a hold rating to a sell rating in a research note released on Thursday morning.

A number of other brokerages also recently weighed in on DCTH. HC Wainwright reiterated a buy rating and issued a $22.00 target price on shares of Delcath Systems in a report on Tuesday, August 6th. Craig Hallum began coverage on shares of Delcath Systems in a research report on Friday, June 28th. They set a buy rating and a $18.00 price objective for the company. Finally, Stephens reiterated an overweight rating and set a $25.00 target price on shares of Delcath Systems in a research report on Tuesday, August 6th.

Delcath Systems Stock Down 0.9 %

DCTH opened at $9.00 on Thursday. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $11.74. The company has a fifty day moving average of $8.81 and a 200-day moving average of $7.08. The stock has a market cap of $250.07 million, a PE ratio of -3.40 and a beta of 0.78.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The business had revenue of $7.77 million for the quarter, compared to analyst estimates of $5.00 million. During the same quarter in the previous year, the business posted ($0.58) earnings per share. Sell-side analysts anticipate that Delcath Systems will post -1.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC acquired a new stake in Delcath Systems in the fourth quarter valued at approximately $4,918,000. ADAR1 Capital Management LLC bought a new position in shares of Delcath Systems in the 4th quarter worth $962,000. Vanguard Group Inc. grew its position in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after purchasing an additional 161,678 shares during the period. BVF Inc. IL increased its stake in Delcath Systems by 23.1% during the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after purchasing an additional 225,918 shares in the last quarter. Finally, Levin Capital Strategies L.P. raised its holdings in Delcath Systems by 12.2% during the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock worth $262,000 after buying an additional 5,969 shares during the last quarter. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.